TR 012001
Alternative Names: TR-012001Latest Information Update: 21 Jun 2024
At a glance
- Originator SNLD
- Class Antiparkinsonians
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Parkinson's disease
Most Recent Events
- 30 May 2024 SNLD completes a phase-II trial in Parkinson's disease in Japan (Intranasal) (NCT06212089)
- 09 Feb 2024 SNLD completes a phase I trial in Parkinson's disease in Japan (Intranasal), prior to February 2024 (jRCT2031210658)
- 28 Sep 2023 Phase-II clinical trials in Parkinson's disease in Japan (Intranasal) (NCT06212089)